David H. G. Smith
Integrium
Tustin
California 92780
USA
Name/email consistency: high
- Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension. Smith, D.H. Drugs (2008)
- Dose-response characteristics of olmesartan medoxomil and other angiotensin receptor antagonists. Smith, D.H. Am. J. Cardiovasc. Drugs (2007)
- Fixed-dose combination antihypertensives and reduction in target organ damage: are they all the same? Smith, D.H. Am. J. Cardiovasc. Drugs (2007)
- Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Smith, D.H., Dubiel, R., Jones, M. Am. J. Cardiovasc. Drugs (2005)
- Prospective, randomized, open-label, blinded-endpoint (PROBE) designed trials yield the same results as double-blind, placebo-controlled trials with respect to ABPM measurements. Smith, D.H., Neutel, J.M., Lacourcière, Y., Kempthorne-Rawson, J. J. Hypertens. (2003)
- Treatment of hypertension with an angiotensin II-receptor antagonist compared with an angiotensin-converting enzyme inhibitor: a review of clinical studies of telmisartan and enalapril. Smith, D.H. Clin. Ther (2002)